Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

0
20

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant AZN, +1.98% said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

Write to Kyle Morris at kyle.morris@dowjones.com

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleDow Jones Newswires: China new-home prices fall by most in over six years
Next articleIran denies involvement in Salman Rushdie attack

LEAVE A REPLY

Please enter your comment!
Please enter your name here